21.00

5.79% 1.15

Palatin Technologies Inc. (PTN)

Overview News Price History Option Chain Discussions Forecast Stock Split

Palatin Technologies Inc. stock is traded at $21.00, with a volume of 10,218. It is up +5.79% in the last 24 hours and up +0.19% over the past month. Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Previous Close:

$19.85

Open:

$20.5

24h Volume:

10,218

Relative Volume:

0.30

Market Cap:

$37.22M

Revenue:

$8.96M

Net Income/Loss:

$-9.63M

P/E Ratio:

-17.75

EPS:

-1.1831

Net Cash Flow:

$-15.88M

1W Performance:

-2.23%

1M Performance:

+0.19%

6M Performance:

+22,217%

1Y Performance:

+2,590%

1-Day Range:

$20.45

$21.29

1-Week Range:

$19.50

$23.45

52-Week Range:

$0.0866

$31.00

Palatin Technologies Inc. Stock (PTN) Company Profile

Name

Palatin Technologies Inc.

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

609-495-2200

Address

Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ

Employee

Twitter

@PalatinTech

Next Earnings Date

2024-11-12

Latest SEC Filings

PTN's Discussions on Twitter

Compare PTN vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTN Palatin Technologies Inc.	21.00	37.22M	8.96M	-9.63M	-15.88M	-1.1831
VRTX Vertex Pharmaceuticals Inc	454.97	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	31.97B	606.42M	-1.28B	-997.58M	-6.403

Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-25	Initiated	Laidlaw	Buy
Dec-03-25	Initiated	Alliance Global Partners	Buy
Jun-05-15	Reiterated	Canaccord Genuity	Buy
Jan-12-15	Reiterated	ROTH Capital	Buy
May-23-12	Initiated	Noble Financial	Buy
Jan-23-07	Initiated	Next Generation	Buy

View All

Palatin Technologies Inc. Stock (PTN) Latest News

Mar 22, 2026

Palatin Technologies stock faces volatility amid bremelanotide sales updates and pipeline advancemen - AD HOC NEWS

Mar 22, 2026

Mar 20, 2026

Palatin’s Case Strengthens as Rhythm’s FDA Approval Validates Hypothalamic Obesity Market (PTN) - TradingView

Mar 20, 2026

Palatin Technologies (PTNT) Insider Trading Activity 2026 $PTNT - MarketBeat

Mar 20, 2026

Mar 18, 2026

Palatin Technologies (PTNT) 10K Form and SEC Filings 2026 $PTNT - MarketBeat

Mar 18, 2026

Mar 17, 2026

PTN Earnings History & Surprises | EPS & Revenue Results | PALATIN TECHNOLOGIES INC (NYSEARCA:PTN) - ChartMill

Mar 17, 2026

Mar 13, 2026

PTN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 13, 2026

Mar 12, 2026

PTN Technical Analysis | Trend, Signals & Chart Patterns | PALATIN TECHNOLOGIES INC (NYSEARCA:PTN) - ChartMill

Mar 12, 2026

Mar 06, 2026

PTN Stock Price, Quote & Chart | PALATIN TECHNOLOGIES INC (NYSEARCA:PTN) - ChartMill

Mar 06, 2026

Mar 04, 2026

Operating cash flow per share of Palatin Technologies, Inc. – LSE:0KF3 - TradingView

Mar 04, 2026

EBIT per share of Palatin Technologies, Inc. – LSE:0KF3 - TradingView

Mar 04, 2026

Mar 02, 2026

Dry Eye Disease Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Palatin Technologies, Novaliq, mc2 therapeutics - Barchart.com

Mar 02, 2026

Feb 27, 2026

PTN Should I Buy - Intellectia AI

Feb 27, 2026

Feb 26, 2026

Palatin Techs (PTN) Stock Analysis Report | Financials & Insights - Benzinga España

Feb 26, 2026

Feb 21, 2026

Palatin Technologies (PINK:PTNT) Share Price Crosses Above 200-Day Moving Average – Here’s What Happened - Defense World

Feb 21, 2026

Feb 19, 2026

Palatin to test 2 obesity-targeting drugs for PWS in clinical trials this year - Prader-Willi Syndrome News

Feb 19, 2026

Palatin Technologies Q2 Earnings Call Highlights - Defense World

Feb 19, 2026

Feb 18, 2026

Palatin Technologies’ Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline (NYSE: PTN) - TipRanks

Feb 18, 2026

Palatin Technologies, Inc. (AMEX:PTN) Q2 2026 Earnings Call Transcript - Insider Monkey

Feb 18, 2026

Palatin Technologies' Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline (NYSE: PTN) - TradingView

Feb 18, 2026

Earnings call transcript: Palatin Technologies Q2 2026 reveals challenges By Investing.com - Investing.com South Africa

Feb 18, 2026

Feb 17, 2026